What is the value of Kimberly-Clark's proposed takeover of Kenvue, and which regulatory body has it formally approached for approval?

The proposed takeover is valued at $40 billion, and Kimberly-Clark has formally requested permission from the European Union regulators — specifically, the European Commission — for the deal, as confirmed by documents published on the EU Commission's website.

What are the key financial and strategic expectations Kimberly-Clark has disclosed for the Kenvue acquisition?

Kimberly-Clark expects the deal to close in the second half of 2026, generate $2.1 billion in annual cost savings, and result in a combined company with approximately $32 billion in annual revenues — driven by Kenvue’s portfolio including Listerine, Aveeno, and Neutrogena.

Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

Aug 28, 2026

Kimberly-Clark has requested EU regulatory approval for its proposed $40 billion acquisition of Kenvue. The deal, expected to close in late 2026, aims to combine portfolios for roughly $32 billion in annual revenue.

reuters

2026-08-06

Kenvue Misses Quarterly Estimates as Inflation Squeezes Margins

2026-08-28

Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

Kimberly-Clark seeks EU approval for $40 billion Kenvue deal

FAQ